关于我们
Arbele is a locally grown pharmaceutical biotech focused on immunotherapy of cancers, immune disorders and neurological diseases. The company founding team has a strong combination of business development and pharmaceutical R&D, with an accumulation of >30 year experience in multinational drug companies. Our motto is to excel patient healthcare through innovation and breakthrough. Our mission is to deliver innovative and cost-effective therapeutics to treat diseases of unmet needs. We focus on antibody-based therapeutic platforms, including chimeric antigen receptor (CAR)-T and Bi-specific antibody technology, while leveraging new technology on CRISPR genome editing. Our culture ingredients are “integrity and social values”.
- 网站
-
https://arbelebio.com/
Arbele的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Bellevue，Washington
- 类型
- 私人持股
- 领域
- Immune Oncology、Stem cells、Biopharmaceutics、Biomarkers、In-vitro diagnostics和CAR therapy
地点
Arbele员工
动态
-
?? We are thrilled to announce strategic collaboration with BioAI in precision oncology using artificial intelligence (AI) to advance targeted immunotherapeutics of bispecific T-cell engagers (TCEs) and antibody-drug conjugates (ADCs). ?? We have also entered a strategic alliance with Chime Biologics to accelerate chemistry, manufacturing and control (CMC) process development of the novel designs of ADCs and TCEs. The partnership supports multiple pipelines of about 10 first-in-class and best-in-class immunotherapeutics, including monoclonal, bispecific/biparatopic and TriAx antibodies within the coming 3 years. The collaboration will ensure Arbele continues to have at least 1-2 new molecular entities (NMEs) successfully filing for investigational new drug (IND) application and entering clinical studies in the next 5 years without any technical and supply-chain interruptions. Read more in our press release below. https://lnkd.in/gPGWWR33 #AIoncology #PrecisionMedicine #Immunotherapeutics #Biotech #Diagnostics #CMC #ProcessDevelopment
Arbele Announces Strategic Collaborations on AI Precision Oncology and Manufacturing to Advance CDH17-Targeted Immunotherapeutics
prnewswire.com
-
Arbele转发了
New Opening For RA Head
Head of Regulatory Affairs Job in North Sydney, Sydney NSW - SEEK
seek.com.au
-
New Opening For RA Head
Head of Regulatory Affairs Job in North Sydney, Sydney NSW - SEEK
seek.com.au
-
?? We’re excited to partner with BioAI in this innovative collaboration! By combining BioAI's PredictX platform with Arbele's data, we’re taking an important step forward in advancing AI-driven biomarker screening for colorectal cancer and more! Together, we aim to push the boundaries of personalized medicine, creating more effective, tailored treatment options for patients with gastrointestinal cancers. Looking forward to what we will accomplish together in this journey towards revolutionizing patient care and improving outcomes for those battling high-mortality cancers. #Partnership #AI #PrecisionMedicine #Oncology #Innovation
?? Exciting News ?? We are thrilled to announce a strategic partnership with Arbele to advance predictive AI models in oncology clinical trials. ?? This collaboration will harness BioAI's PredictX platform and Arbele’s clinical trial data to drive AI-powered biomarker screening for colorectal cancer (CRC). ?? The goal is to create cutting-edge companion diagnostic tests that enhance patient selection and treatment efficacy, revolutionizing personalized medicine for gastrointestinal cancers. ??? As our CEO, Thomas Colarusso, put it: "We are excited to apply our novel AI platform to accelerate the development of innovative treatment options for gastrointestinal cancers. This partnership underscores our commitment to transforming patient care through advanced machine learning." ?? Together, we are paving the way for precision medicine breakthroughs to help patients globally with high-mortality cancers. Learn more about this exciting partnership in the full article below! ??
BioAI Announces Strategic Partnership with Arbele Bio to advance Predictive AI-Models in Oncology Clinical Trials
prnewswire.com
-
Our CTO Tony Wong had a dynamic panel session today, where he explored the future trends shaping China's biopharma industry. The insights shared were truly exciting and indicative of the rapid innovation happening in this space. #biopharma #Innovation #Healthcare #FutureTrends
What a phenomenal discussion on China’s biopharma industry at the BIOHK roundtable! ?? A massive thank you to all those who tuned in and contributed to the conversation on shaping the next decade of healthcare breakthroughs. ? Kudos to the moderator, Peter Pang 彭彼得, our SVP and General Manager of the Shanghai Innovation Center,?for expertly guiding us through the nuances of innovation and strategy! ? And a standing ovation to our stellar panelists: Dr. Tony Wong, CTO, Arbele Dr. Li Ming, CEO，滬港中科國際生物科技有限公司 Dr. Michael Wong, R&D Director,?Immunocure Inc Together, we can chart a course for disruptive discoveries and biotech breakthroughs! ?? ? #Biopharma #Innovation #FutureOfHealth #PharmaLeadership #FutureOfHealth
-
-
-
-
-
+1
-
-
Our CTO Tony Wong will be part of the panel to discuss the trends in the next decade for China Biopharma. Be sure to join him and the rest of the panelists this Friday, 13 Sep at Hong Kong Convention and Exhibition Center Main Hall. #BIOHK2024 #trends #biopharma #China #panel #panelist
We invite you to join industry leaders on Sep 13 for a thought-provoking BIOHK roundtable on how China's biopharma innovation unfolds over the next decade?? ? Peter Pang 彭彼得, our SVP and General Manager of the Shanghai Innovation Center, will be moderating?? With over 20 years of pioneering industry experience, Dr. Pang is well-placed to guide this discussion. ? ?? Panelists Include: Dr. Piers Ingram, CEO, Hummingbird Bioscience Dr. Tony Wong, CTO, Arbele Dr. Li Ming, CEO, 滬港中科國際生物科技有限公司 Dr. Michael Wong, R&D Director, Immuno Cure Expect an engaging discussion that delves deep into biopharma breakthroughs, global ecosystem developments, and the disruptive innovations that will define the decade ahead! ?? ? Join us at the Hong Kong Convention and Exhibition Centre Hall-3D 3E Main Hall, Sep 13, 2024 (Fri), 10-11 am ?? ? #Biopharma #Innovation #FutureOfHealth #PharmaLeadership
-
-
? Join us at ESMO - European Society for Medical Oncology where we share our work on companion diagnostics for cabotamig in GI cancers. We are working towards establishing the GOLD standard in CDH17 diagnostics. ?? ??????: ???????? ??????????: ?????????????????????? ???? ?? ????????????????-???? (??????????) ???????????????????????????????????????? ?????????? ?????? ?????? ???? ?? ?????????????????? ???????????????????? ?????? ?????????????????? ???? ???????????????????????????????? ??????????????. TibTech Limited (Tiberias Limited) #ESMO2024 #Diagnostics #GIcancers #gastrointestinalcancers #immunohistochemistry #IHC #biotech #CompanionDiagnostic #Oncology
-
-
???????????????????? ???? ???????????? We are looking for a partner to provide cell line development and antibody production services for a few assets in our pipeline. For more information, please refer to our website. https://lnkd.in/grCfywNY #tender #celllinedevelopment #antibodyproduction #partner
Posts & Notices
https://www.arbelebio.com
-
???????????????? ?????? ???????????? ???????????? ????????????: ???? ?????????????????? ?????????????????? ???????? ?????? ?????????????? ?????? ??????, ???????? ?????? We’re thrilled to share an insightful conversation between our founder and CEO, John LUK and PharmaBoardroom. In this interview, John dives into the journey and inspiration behind founding Arbele, our unwavering passion for daily innovation, and the challenges faced during clinical trials. He also discusses the exciting potential of our groundbreaking innovations to revolutionize cancer treatment. Don’t miss this opportunity to learn more about Arbele’s mission and vision. Click the link to read the full interview! https://lnkd.in/g68UF8nf #Biotech #Innovation #CancerResearch #Leadership #ClinicalTrials #Healthcare #Pharma
John Luk – Chairman & Founder, Arbele
https://pharmaboardroom.com